Compare Gilead Sciences, Inc. (GILD) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Advanced Drainage Systems Inc — how do they compare? Gilead Sciences, Inc. trades at $133.04 (market cap $163.51B), while Advanced Drainage Systems Inc trades at $153.33 (market cap $11.59B). The key difference: Gilead Sciences, Inc. is far larger — about 14.1× Advanced Drainage Systems Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | WMS | |
|---|---|---|
Market Cap | $163.51B | $11.59B |
Sector | Health | Industrials |
52-Week High | $155.80 | $175.38 |
52-Week Low | $108.22 | $110.89 |
Enterprise Value | $178.05B | $13.16B |
Dividend Yield | 2.49% | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
WMS trades at $151.04, up 2.32% today, with a bullish technical signal from moving averages. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $1.07 exceeding the $0.936 estimate. Revenue for 2025 was $2.90B, with a net income margin of 13.98%. Recent news includes a dividend increase and a scheduled Investor Day.
The outlook is supported by strong profitability and a consensus price target of $184.43, implying 22% upside. Risks include a recent Zacks Strong Sell rating and projected earnings decline in 2026. Investor sentiment is mixed, with 41% of analysts rating Buy but some institutional selling noted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
